DateMay 19, 2020 - 9:00am
In the US, 60,000 patients are diagnosed with peritoneal metastases annually. As options and outcomes for other metastatic sites have continued to improve, survival for patients with peritoneal disease remains less than 1 year. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS HIPEC) entails aggressive local control of disease as well as intraperitoneal chemotherapy, can meaningfully increase survival for patients with advanced cancer, often extending survival by years compared to systemic therapy alone. This intensive strategy comes at a cost, and complications, lengthy hospitalizations, and readmissions are common following surgery.
Dr. Rieser will present her retrospective work examining perioperative outcomes and disparities within CRS HIPEC care delivery at UMPC and discuss the framework of a pilot trial to examine the feasibility and efficacy of a prehabilitation program for patients undergoing CRS HIPEC at UPMC.
Location and Address
UPMC Presbyterian, F-1275 Conference Room